Williams L, Newton G, Roberts K, Finlayson S, Brabbins C. Clozapine-resistant schizophrenia : a positive approach. Br J Psychiatry. 2002;181:184–7.

Article  PubMed  Google Scholar 

De Berardis D, Rapini G, Olivieri L, Di Nicola D, Tomasetti C, Valchera A, et al. Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. Ther Adv Drug Saf. 2018;9(5):237–56 Available from: http://www.ncbi.nlm.nih.gov/pubmed/29796248. Cited 5 Jul 2019.

Article  PubMed Central  PubMed  Google Scholar 

Taylor DM. Clozapine for Treatment-Resistant Schizophrenia: Still the Gold Standard? CNS Drugs. 2017;31:177–80 Available from: http://www.ncbi.nlm.nih.gov/pubmed/28258419. Cited 15 Sep 2019.

Article  PubMed  Google Scholar 

Atkinson JM, Douglas-Hall P, Fischetti C, Sparshatt A, Taylor DM. Outcome following clozapine discontinuation: A retrospective analysis. J Clin Psychiatry. 2007;68(7):1027–30.

Article  CAS  PubMed  Google Scholar 

Citrome L, McEvoy JP, Saklad SR. A Guide to the Management of Clozapine-Related Tolerability and Safety Concerns. Clin Schizophr Relat Psychoses. 2016;10:163–77 Available from: http://clinicalschizophrenia.org/doi/10.3371/CSRP.SACI.070816.

Article  PubMed  Google Scholar 

Davis MC, Fuller MA, Strauss ME, Konicki PE, Jaskiw GE. Discontinuation of clozapine: a 15-year naturalistic retrospective study of 320 patients. Acta Psychiatr Scand. 2014;130:30–9 Available from: http://www.ncbi.nlm.nih.gov/pubmed/24299466. Cited 9 Aug 2017.

Article  CAS  PubMed  Google Scholar 

Legge SE, Hamshere M, Hayes RD, Downs J, O’Donovan MC, Owen MJ, et al. Reasons for discontinuing clozapine: A cohort study of patients commencing treatment. Schizophr Res. 2016;174:113–9 Available from: https://linkinghub.elsevier.com/retrieve/pii/S0920996416302225. Cited 5 Jul 2019.

Article  PubMed Central  PubMed  Google Scholar 

Hellewell JS. Treatment-resistant schizophrenia: reviewing the options and identifying the way forward. J Clin Psychiatry. 1999;60(Suppl 2):14–9 Available from: http://www.ncbi.nlm.nih.gov/pubmed/10625195. Cited 9 Aug 2017.

PubMed  Google Scholar 

Kasper S, Saya L, Tekin B, Loze J-Y. How to improve adherence to antipsychotic treatment: Outcomes of the IMproving PAtient outComes in psychiaTry (IMPACT) Berlin 2009 meeting workshop. Int J Psychiatry Clin Pract. 2009;13:245–52 Available from: http://www.tandfonline.com/doi/full/10.3109/13651500903359861. Cited 10 Aug 2019.

Article  PubMed  Google Scholar 

Lloyd H, Lloyd J, Fitzpatrick R, Peters M. The role of life context and self-defined well-being in the outcomes that matter to people with a diagnosis of schizophrenia. Heal Expect. 2017;20(5):1061–72 Available from: http://doi.wiley.com/10.1111/hex.12548. Cited 9 Aug 2019.

Article  Google Scholar 

Mistry H, Osborn D. Underuse of clozapine in treatment-resistant schizophrenia. Adv Psychiatr Treat. 2011;17:250–5 Available from: http://apt.rcpsych.org/cgi/doi/10.1192/apt.bp.110.008128.

Article  Google Scholar 

Ucok A, Yağcıoğlu EA, Yıldız M, Kaymak SU, Saka MC, Taşdelen R, et al. Reasons for clozapine discontinuation in patients with treatment-resistant schizophrenia. Psychiatry Res. 2019;1(275):149–54.

Article  Google Scholar 

De Silva H, Pai N. No longer on clozapine:where are they now? Proceedings of The Royal Australian and New Zealand College of Psychiatrists Congress, 11–15 May 2014 Perth. In: Australian & New Zealand Journal of Psychiatry [Internet]. Perth: The Royal Australian and New Zealand College of Psychiatrists; 2014 [cited 2017 Aug 17]. p. [online]. Available from: http://journals.sagepub.com/doi/10.1177/0004867414529061

Nair B, Maccabe JH. Making clozapine safer: Current perspectives on improving its tolerability. Future Neurol. 2014;9:313–22 Available from: http://www.futuremedicine.com/doi/10.2217/fnl.14.23. Cited 10 Aug 2017. Future Medicine Ltd London, UK

Article  CAS  Google Scholar 

Conley RR, Kelly DL. Management of treatment resistance in schizophrenia. Biol Psychiatry. 2001;50(11):898–911 Available from: http://www.ncbi.nlm.nih.gov/pubmed/11743944. Cited 9 Aug 2017.

Article  CAS  PubMed  Google Scholar 

Hofer A, Kemmler G, Eder U, Honeder M, Hummer M, Fleischhacker WW. Attitudes towards antipsychotics among regularly attendees with schizophrenia. J Clin Psychiatry. 2002;63(1):49–53.

Article  PubMed  Google Scholar 

Glick ID, Correll CU, Altamura AC, Marder SR, Csernansky JG, Weiden PJ, et al. Mid-Term and Long-Term Efficacy and Effectiveness of Antipsychotic Medications for Schizophrenia. J Clin Psychiatry. 2011;72(12):1616–27 Available from: http://www.ncbi.nlm.nih.gov/pubmed/22244023. Cited 9 Aug 2017.

Article  CAS  PubMed  Google Scholar 

Nsamenang SA, Hirsch JK. Positive psychological determinants of treatment adherence among primary care patients. Prim Health Care Res Dev. 2015;16:398–406. Available from: https://doi.org/10.1017/S1463423614000292. Cited 10 Aug 2019.

Article  PubMed  Google Scholar 

Diez-Perez A, Adachi JD, Adami S, Anderson FA, Boonen S, Chapurlat R, et al. Risk factors for treatment failure with antiosteoporosis medication: The global longitudinal study of osteoporosis in women (GLOW). J Bone Miner Res. 2014;29(1):260–7.

Article  CAS  PubMed  Google Scholar 

Siu SWK, Leung PPY, Liu RKY, Leung TW. Patients’ views on failure to gain expected clinical beneficial outcomes from participation in palliative medicine clinical trials. Am J Hosp Palliat Med. 2013;30(3):239–48.

Article  Google Scholar 

Thomas RH, Mullins JM, Hammond CL, Smith PEM, Kerr MP. The importance of the experiences of initial diagnosis and treatment failure when switching antiepileptic drugs. Epilepsy Behav. 2013;29(3):492–6. Available from: https://doi.org/10.1016/j.yebeh.2013.08.025.

Article  PubMed  Google Scholar 

Biringer E, Davidson L, Sundfør B, Ruud T, Borg M. Experiences of support in working toward personal recovery goals: a collaborative, qualitative study. BMC Psychiatry. 2016;16(426):1–14 Available from: http://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-016-1133-x. Cited 10 Aug 2019.

Google Scholar 

Tournier M, Neumann A, Pambrun E, Weill A, Chaffiol JP, Alla F, et al. Conventional mood stabilizers and/or second-generation antipsychotic drugs in bipolar disorders: A population-based comparison of risk of treatment failure. J Affect Disord. 2019;1(257):412–20.

Article  Google Scholar 

de Kuijper GM, Hoekstra PJ. An Open-Label Discontinuation Trial of Long-Term, Off-Label Antipsychotic Medication in People With Intellectual Disability: Determinants of Success and Failure. J Clin Pharmacol. 2018;58(11):1418–26.

Article  PubMed  Google Scholar 

Park-Wyllie L, van Stralen J, Castillon G, Sherman SE, Almagor D. Differences in Adverse Event Reporting Rates of Therapeutic Failure Between Two Once-daily Extended-release Methylphenidate Medications in Canada: Analysis of Spontaneous Adverse Event Reporting Databases. Clin Ther. 2017;39(10):2006–23.

Article  CAS  PubMed  Google Scholar 

Di Gennaro F, Pizzol D, Cebola B, Stubbs B, Monno L, Saracino A, et al. Social determinants of therapy failure and multi drug resistance among people with tuberculosis: A review. Tuberculosis. 2017;1(103):44–51.

Article  Google Scholar 

Choi H, Hayat MJ, Zhang R, Hirsch LJ, Bazil CW, Mendiratta A, et al. Drug-resistant epilepsy in adults: Outcome trajectories after failure of two medications. Epilepsia. 2016;57(7):1152–60.

Article  CAS  PubMed  Google Scholar 

Brooks H, Harris K, Bee P, Lovell K, Rogers A, Drake R. Exploring the potential implementation of a tool to enhance shared decision making (SDM) in mental health services in the United Kingdom: a qualitative exploration of the views of service users, carers and professionals. Int J Ment Health Syst. 2017;11(42):1–12 Available from: http://ijmhs.biomedcentral.com/articles/10.1186/s13033-017-0149-z. Cited 10 Aug 2019.

Google Scholar 

Bottiroli S, Viana M, Sances G, Ghiotto N, Guaschino E, Galli F, et al. Psychological factors associated with failure of detoxification treatment in chronic headache associated with medication overuse. Cephalalgia. 2016;36(14):1356–65.

Article  CAS  PubMed  Google Scholar 

Barnes T, McEvedy JB, Nelson H. Management of treatment resistant schizophrenia unresponsive to clozapine. Br J Psychiatry. 1996;169(supplement 31):31–40.

Article  Google Scholar 

Tungaraza TE, Farooq S. Clozapine prescribing in the UK: views and experience of consultant psychiatrists. Ther Adv Psychopharmacol. 2015;5(2):88–96 Available from: http://www.ncbi.nlm.nih.gov/pubmed/26240748. Cited 9 Aug 2017.

Article  PubMed Central  PubMed  Google Scholar 

Angermeyer MC, Löffler W, Müller P, Schulze B, Priebe S. Patients’ and relatives’ assessment of clozapine treatment. Psychol Med. 2001;31(3):509–17.

Article  CAS  PubMed  Google Scholar 

Sowerby C, Taylor D. Cross-sector user and provider perceptions on experiences of shared-care clozapine: A qualitative study. BMJ Open. 2017;7(9):e017183.

Article  PubMed Central  PubMed  Google Scholar 

Hanlon MC, O’Brien AP, Maclsaac P, Fogarty M, Hunt M, Drinkwater V, et al. Quality clozapine care (QC2): Using the patient journey to understand the lived experience of taking clozapine, to improve value-based person-centered care. 26th European Congress of Psychiatry, 3–6 March 2018 Nice. In: European Psychiatry. Nice: Elsevier Inc.; 2018. p. vol 28.

Murphy K, Coombes I, McMillan S, Wheeler AJ. Clozapine and shared care: The consumer experience. Aust J Prim Health. 2018;24(6):455–62.

Article  PubMed  Google Scholar 

John AP, Burrows S, Stanley S, Acabo C, Shymko G, Jaworska A, et al. Demographic and clinical characteristics of patients who recommence clozapine following therapy interruptions. Acta Psychiatr Scand [Internet]. 2021. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/acps.13394. Cited 13 Jan 2022.

Mental Health Forum. Has anyone successfully stopped Clozapine without going onto a different medication? [Internet]. online. 2015 [cited 2016 Jul 24]. Available from: https://www.mentalhealthforum.net/forum/thread94204.html

Patient Forum. Clozapine discontinuation – some experiences and a new animal model of schizophrenia | advancingschizophreniatherapeutics [Internet]. online. 2015 Available from: https://advancingschizophreniatherapeutics.wordpress.com/2015/08/06/clozapine-discontinuation-some-experiences-and-a-new-animal-model-for-schizophrenia/ Cited 24 Jul 2016.

Psych-forum. Clozapine withdrawal. : Schizophrenia Forum - Psych forums [Internet]. www.psychforums.com. 2013. Available from: http://www.psychforums.com/schizophrenia/topic131797.html Cited 24 Jul 2016

Kaminskiy E, Zisman-Ilani Y, Ramon S. Barriers and Enablers to Shared Decision Making in Psychiatric Medication Management: A Qualitative Investigation of Clinician and Service Users’ Views. Front Psychiatry. 2021;12(June):3–5.

Google Scholar 

Leydon GM, Rodgers L, Kendrick T. A qualitative study of patient views on discontinuing long-term selective serotonin reuptake inhibitors. Fam Pract. 2007;24(6):570–5.

Article  PubMed  Google Scholar 

Roe D, Jones N, Hasson-Ohayon I, Zisman-Ilani Y. Conceptualization and Study of Antipsychotic Medication Use: From Adherence to Patterns of Use. Psychiatr Serv. 2021;72(12):1464–6.

Article  PubMed  Google Scholar 

Zisman-Ilani Y, Lysaker PH, Hasson-Ohayon I. Shared risk taking: Shared decision making in serious mental illness. Psychiatr Serv. 2021;72(4):461–3.

Article  PubMed  Google Scholar 

Zisman-Ilani Y, Roth RM, Mistler LA. Time to Support Extensive Implementation of Shared Decision Making in Psychiatry. JAMA Psychiatry. 2021;78(11):1183–4 Available from: https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2783294. Cited 11 Dec 2022.

Article